跳至主要内容
临床试验/NCT06462703
NCT06462703招募中不适用

Tablet-based Application for Cognitive Therapy In the Care of Brain Injury

Klinikum Floridsdorf2 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2023年3月2日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
200
试验地点
2
主要终点
Mean change from baseline in CERAD-plus scores

研究概览

简要总结

Cognitive impairments such as deficits in attention, executive functions, perception, language, speech, arithmetics, and memory are very common symptoms after acquired brain injury, which can be caused by neurological diseases such as stroke, cerebral haemorrhage or traumatic brain injury. Around 83% of patients with brain injury suffer from a sequelae of cognitive impairments.

Since the effects caused by neurological diseases can vary greatly from person to person, intensive and individual neuro-rehabilitation is necessary to help patients return to an independent life in the best possible way. In the DACH area (i.e., in Germany, Austria, and Switzerland), patients with cognitive impairments following brain injuries generally receive this intensive and interdisciplinary treatment while being hospitalised in an inpatient clinic following acute medical care.

However, once they leave inpatient care facilities, there are insufficient treatment options readily available to them due to limitations/shortages in the healthcare system's resources, although studies indicate that an increase in therapy time (both in outpatient settings at home or in care facilities) enables greater, long-term rehabilitation progress and faster reintegration and participation in everyday life. Thanks to recent technical advancements, digital treatment options now promise the availability of sufficiently frequent and intensive treatment outside of clinic settings. In that context, the myReha therapy software (available as an app on iOS ad Android tablets), a certified medical device, was developed to enable patients to receive individualised and intensive therapy regardless of the healthcare system's constraints. To test the effectiveness of the myReha therapy software, in this two-arm, randomised, controlled study, patients in the intervention group receive treatment through the myReha therapy software in addition to their usual standard care (i.e., care-as-usual - CAU), while the control group only receives CAU. Treatment outcomes (i.e., rehabilitation progress) are measured based on the CERAD-plus.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Cognitive impairment (deficits in attention, arithmetics, executive functions, memory, language, perception) according to CERAD-plus after a diagnosed brain injury ≥ 4 weeks ago
  • No prior experience with a therapy app for neurological deficits
  • Motivation to use the therapy software regularly
  • Sufficiently good German language skills prior to the brain injury

排除标准

  • Being unable to use a tablet without assistance
  • Severe visual or hearing impairment that interferes with the performance on psychometric testing procedures
  • Any pre-existing speech or language disorder or dementia prior to the onset of brain injury
  • An ongoing outpatient or inpatient rehabilitation at the time of study inclusion or planned rehabilitation of the primary disease during the study period
  • Serious disabling disease(s) which, in the opinion of the investigator, would preclude participation in the study until the follow-up phase
  • Pregnancy

结局指标

主要结局

Mean change from baseline in CERAD-plus scores

时间窗: From enrolment to the end of treatment at 12 weeks

次要结局

  • Mean change from baseline in BIAS-R scores(From enrolment to the end of treatment at 12 weeks)
  • Mean change from baseline in CETI score(From enrolment to the end of treatment at 12 weeks)
  • Mean change from baseline in HADS-D scores(From enrolment to the end of treatment at 12 weeks)
  • Mean change from baseline in EQ-5D-5L scores(From enrolment to the end of treatment at 12 weeks)

研究者

发起方
Klinikum Floridsdorf
申办方类型
Other
责任方
Principal Investigator
主要研究者

Peter Lackner

Prof. Dr.

Klinikum Floridsdorf

研究点 (2)

Loading locations...

相似试验